Note: Descriptions are shown in the official language in which they were submitted.
CA 02750148 2014-12-31
.)
PHARMACEUTICAL DOSAGES DELIVERY SYSTEM
FIELD OF THE INVENTION
[001] This invention relates generally to electronic devices and, more
specifically, to electronic devices that are part of a communication system
that
uses conduction to communicate information.
INTRODUCTION
[002] Prescription medications are effective remedies for many patients when
taken properly. However, studies show that on average, about 50% of patients
do
not comply with prescribed medication regimens. A low rate of adherence with
medication regimens results in a large number of hospitalizations and
admissions
to nursing homes every year. In the United States alone, it has recently been
estimated that costs resulting from patient non-adherence amount to over $100
billion annually.
[003] One situation where patient adherence is of particular importance is in
the
context of clinical studies. Non-adherence in the clinical trial setting has
long-
range consequences far beyond the few hundred patients who might be involved
in a trial. To the extent that non-adherence occurs without a correction
factor, it
may have effects ranging from failure to gain FDA approval to the necessity
for
increasing the recommended dose beyond that which would be required of a fully
compliant population. Such an elevated dose could cause a higher incidence of
side effects, which in turn may lead to further non-adherence.
[004] Clinical studies typically enroll patients to undergo specific drug
treatment
regimens with the goal of testing hypotheses related to the effects of drug
treatment on medically relevant clinical endpoints. Such studies might
measure,
for example, the relationship between alternative drug treatments with any of
a
wide variety of clinical endpoints, ranging from physiological, biochemical or
psychological measurements, to manifestations of disease, patient survival or
1
CA 02750148 2014-12-31
t
quality of life. In addition, drug treatments must also be related to any
observed
adverse events in an effort to identify rare adverse reactions or interactions
with
other medications.
[005] The ability to reliably correlate highly specific drug treatment
regimens,
including dosage and administration methods, with both efficacy and safety
depends to a great extent on the certainty of knowledge that every patient has
followed the prescribed treatment regimen. Monitoring of patient adherence,
including the exact time of administration for medications, is therefore of
great
value to clinical trial sponsors as well as the pharmaceutical industry in
general.
[006] Therefore, what is needed is a system and method for tracking the dosage
administered and the time timing of the administration.
SUMMARY
[007] Devices of the invention include a carrier component and a cap
configured
to seal an internal volume of the carrier component, where the cap includes a
communication device that encodes information in current flow. The device
includes an ingestible event marker or an ionic emission module identifier
that
use conduction through conducting fluid in contact with the device. Devices of
invention find use in preparing a pharmaceutical dosage. Additional aspects of
the invention include dosages prepared in accordance with the methods of the
invention. Dosages prepared according to embodiments of the invention find use
in a variety of different applications, including clinical trials.
BRIEF DESCRIPTION OF THE FIGURES
[008] FIG. 'IA provides a partial cut-away and perspective front view of a
pharmaceutical dosage delivery system according to the present invention with
a
current signature producing device positioned on the exterior of the delivery
system.
2
CA 02750148 2014-12-31
= t
[009] FIG. 18 provides a partial cut-away and perspective front view of a
pharmaceutical dosage delivery system according to the present invention with
a
current signature producing device positioned on the interior of the delivery
system.
[010] FIG. 2A provides an exploded perspective view of the pharmaceutical
dosage delivery system of FIG. 1A.
[011] FIG. 2B provides an exploded perspective view of the pharmaceutical
dosage delivery system of FIG. 1B.
[012] FIG. 3A provides a bottom view of a cap used in the pharmaceutical
dosage of FIG. 1 in accordance with the present invention.
[013] FIG. 3B provides a side view of the cap of FIG 3A.
[014] FIG. 3C provides a perspective view of the cap of FIG 3A.
[015] FIG. 4 provides a cross-sectional view of a pharmaceutical dosage with
an
over-cap according to the present invention.
DETAILED DESCRIPTION
[016] Devices of the invention include a carrier component and a cap
configured
to seal an internal volume of the carrier component, where the cap includes an
ingestible event marker identifier. Devices of invention find use in preparing
a
pharmaceutical dosage. Additional aspects of the invention include dosages
prepared in accordance with the methods of the invention. Dosages prepared
according to various aspects of the invention find use in a variety of
different
applications, including clinical trials.
[017] In describing the invention in greater detail, devices of the invention
and
methods for their use in preparing a pharmaceutical dosage are reviewed first,
followed by a discussion of the utility of such methods, and assemblies and
systems involving the same. Also reviewed in greater detail below are kits for
practicing methods of the invention.
[018] As summarized above, devices and methods for their use in preparing
pharmaceutical dosages are provided. The term "pharmaceutical dosage" refers
to a physically discrete structure that contains a known amount of active
agent,
where the known amount of active agent is one that has been selected for
3
CA 02750148 2014-12-31
=1
administration to a subject at an active agent administration event. A
pharmaceutical dosage therefore contains a predetermined quantity of a
pharmaceutically active agent (also referred to herein simply as an "active
agent"). The amount of pharmaceutically active agent that is present in the
pharmaceutical dosage is calculated to be sufficient to produce a desired
effect
when administered to a subject at an active agent administration event. A
pharmaceutical dosage produced by methods of the invention may have any of a
variety of different configurations. As such, the pharmaceutical dosage may be
cylindrical, spherical or elliptical in shape, or any other convenient shape.
Of
interest are pharmaceutical dosages that have a substantially capsule
configuration, as reviewed in greater detail below.
[019] Devices of the invention include a carrier component and a cap
configured
to seal an internal volume of the carrier component, where the cap includes an
ingestible event marker identifier. These components of the devices may vary,
where different aspects of these components are described in greater detail
below.
[020] Methods of the invention include filling a carrier component with a
pharmaceutically active agent composition and then sealing the carrier
component with a cap to produce the pharmaceutical dosage. The carrier
component is a container that holds an amount of pharmaceutically active agent
composition. Depending on the particular nature of the pharmaceutically active
agent composition (described in greater detail below), the carrier component
may
be configured to hold a variety of types of compositions, including liquids
and
solids, such as powders, tablets, coated particulate compositions, pellets,
beads
and spherules. While the volume of the active agent that the carrier is
configured
to hold may vary, in some instances the carrier may be configured to a
quantity of
active agent ranging from 0 to 1 g, such as 0 to 100 mg and including 0 to 5
mg.
The carrier component may have a variety of different configurations. Examples
of carrier component configurations include, but are not limited to partial
box
shapes, partial spherical shapes, partial ovoid shapes, partial conical
shapes, etc.
[021] One carrier component configuration of interest is a partial-capsule
configuration. Partial-capsule configurations are those configurations having
a
first, open end and a second, closed end, where the open and closed ends are
separated by a distance sufficient to provide a desired internal volume to the
4
CA 02750148 2014-12-31
=
,e.
carrier component. Partial-capsule configurations finding use may have a
variety
of different cross-sectional configurations, where the cross-sectional
configuration
is the shape defined by the walls of the carrier component at the open end.
Cross-sectional configurations of interest include, but are not limited to
circular,
rectangular, triangular, square and oval, as well as irregular cross sectional
configurations.
[022] Partial-capsule configured carrier components of the invention may have
varied dimensions, as desired. In some instances, the length of the carrier
component ranges from 1 mm to 50 mm, such as 5 mm to 30 mm and including
mm to 20 mm. The outer diameter of the carrier component may vary, ranging
in some instances from 1 mm to 30 mm, such as 5 mm to 20 mm and including 5
mm to 10 mm. The inner diameter of the carrier component may also vary,
ranging from 0.5 mm to 29.99 mm, such as 3.0 mm to 19.99 mm and including
3.0 mm to 9.99 mm. The walls of the carrier component may vary, so long as
they are sufficiently thick to hold the pharmaceutically active agent
composition,
where in some instances the walls range in thickness from 0.01 mm to 2 mm,
such as 0.01 mm to 0.2 mm and including 0.01 mm to 0.1 mm. The dimensions
may be constant or variable in the carrier component, as desired. For example,
the inner diameter may be constant along the length of the capsule or may
vary.
[023] Carrier components of the invention, such as partial-capsule configured
carrier components, may be fabricated from any convenient material using any
convenient protocol. Materials of interest from which the carrier components
may
be fabricated include physiologically acceptable polymeric materials that are
used
in conventional pharmaceutical capsule dosages. The materials may be clear or
opaque, and may be colored as desired. Of interest are both rigid and elastic
materials.
[024] Suitable polymers from which carrier components of the invention may be
fabricated include, but are not limited to: gelatins, polyvinyl alcohol (PVA);
natural
and synthetic polysaccharides, including pullulan, carrageenan, xanthan,
chitosan agar gums, and cellulosic materials, such as carboxymethylcellulose,
hydroxypropylmethylcellulose (HPMC), methylcellulose, hydroxyethylcellulose,
hydroxyethyl methylcellu lose, hyd roxypropylcellu lose; polyethylene glycols
(PEGs), polyethylene oxides (PE0s), mixtures of PEGs and PE0s; acrylic and
methacrylic acid based polymers, such as EUDRAGIT ETM, EUDRAGIT LTM
5
CA 02750148 2014-12-31
and/or EUDRAGIT STM methacrylic acid polymers), EUDRAGIT RLTM and/or
EUDRAGIT RSTM ammonium methacrylate copolymers; povidone (polyvinyl
pyrrolidone), polyglycolysed glycerides (such as GELUCIRE 44/14Tm, GELUCIRE
50102TM, GELUCIRE 50113TM and GELUCIRE 53110TM polymers); carboxyvinyl
polymers (such as CARBOPOLTM polymers); polyoxyethylene-polyoxypropylene
copolymers (such as POLOXAMER188Tm polymer); and the like.
[025] The surface of the carrier component may be smooth or comprised of
variegations and/or grooves arranged in any pattern. Where desired, the
carrier
component has compartments or partitions. The carrier component may have
multiple compartments, such that each compartment has different active agent
release characteristics, or contains a different pharmaceutically active agent
composition, for example as described in U.S. Patent Nos. 4,738,724; 5,672,359
and 5,443,461.
[026] The carrier components may be fabricated using any convenient protocol,
including molding, etc. Fabrication protocols of interest include, but are not
limited
to, those described in U.S. Patent Nos.: 5,705,189; 4,576,284; 4,591,475;
4,655,840; 4,738,724; 4,738,817 and 4,790,881. Alternatively, the carrier
component may be obtained from a commercial vendor, such as Qualicaps Inc.,
Whitsett NC.
[027] In methods of the invention, the carrier component may be filled with a
variety of different types of pharmaceutically active agent compositions. The
protocol that is employed to fill the carrier component may vary depending on
the
nature of the pharmaceutically active agent composition. For example, flowable
compositions such as liquids and solids (particulate and spherule compositions
being examples of flowable solids) may be poured into the internal space of
the
carrier component, either manually, using an automated device, or a
combination
thereof, in order to fill the carrier component with the pharmaceutically
active
agent composition. Non-flowable solids, such as tablets or capsules, may be
positioned inside of the internal volume of the carrier component, again
either
manually, using an automated device, or a combination thereof, in order to
fill the
carrier component.
[028] As indicated above, the pharmaceutically active agent compositions may
be solid or liquid compositions. Solid compositions of interest include, but
are not
limited to: powders, pellets, e.g., in the form of beads or spherules, coated
6
CA 02750148 2014-12-31
=
granules and tablets. Liquid compositions of interest may vary, for example in
terms of viscosity, color, etc. Pharmaceutically active agent compositions of
the
invention include a pharmaceutically active agent, either alone or in
combination
with a vehicle, where the vehicle may include one or more different
components,
such as fillers, binders, coloring agents, etc.
[029] As used herein, the term "active agent" includes any compound that
produces a physiological result, for example a beneficial or useful result,
upon
contact with a living organism, such as a human. Active agents are
distinguishable from such vehicle components such as fillers, binders,
coloring
agents, etc. The active agent may be any molecule that is capable of
modulating
a biological process in a living subject. In some instances, the active agent
may
be a substance used in the diagnosis, treatment, or prevention of a disease or
as
a component of a medication. Broad categories of active agents of interest
include, but are not limited to: cardiovascular agents; pain-relief agents,
e.g.,
analgesics, anesthetics, anti-inflammatory agents, etc.; nerve-acting agents;
chemotherapeutic (e.g., anti-neoplastic) agents; etc. Active agents of
interest are
further disclosed in PCT Application Serial No. US2006/016370 published as WO
2006/116718.
[030] The pharmaceutically active agent composition may further include a
vehicle component, as mentioned above. Vehicle components may include one
or more constituents, including but not limited to fillers, binders,
disintegrants,
coloring agents, etc. Vehicle components of interest are further reviewed in
PCT
Application Serial No. US2006/016370 published as WO 2006/116718. Additional
disclosure of components that can be present in compositions of the invention
can be found in Remington's Pharmaceutical Sciences, Mace Publishing
Company, Philadelphia, Pa., 17th ed. (1985).
[031] In some instances, the methods may include providing a filler
composition
that is separate from the active agent composition in the carrier component.
For
example, in some instances the carrier component is filled with both a
pharmaceutically active agent composition and a distinct filler composition,
where
the filler composition may be included for a variety of different purposes.
One
type of filler composition of interest is one that imparts to the
pharmaceutical
dosage composition a density that is greater than stomach fluid. Accordingly,
filler
compositions of interest are ones that impart to the pharmaceutical dosage
7
CA 02750148 2014-12-31
=
composition a density that is 0.8 or greater, such as 1.0 or greater and
including
1.2 or greater. Any convenient material may be employed as a filler
composition,
including the materials described as vehicle components, above.
[032] The filler may also be included to fill any void space present when a
device
or identifier, such as an ingestible event marker (IEM, which is also known as
an
ionic emission module) identifier is placed inside of the carrier components.
The
identifier component of the dosages provides for a number of advantages. The
presence of the identifier allows one to monitor the exact time and frequency
of
medication administration, as well as patient response. This information
obtainable by use of the methods and dosages of the invention can be exploited
in a number of settings, such as, for example, in improving the overall
quality and
accuracy of clinical studies. Using such information, one can readily identify
members of the clinical trial who comply with a treatment regimen and exclude
those that do not in order to obtain more accurate data regarding efficacy of
a
given active agent. Such information can also be combined with various types
of
physiological data in order to obtain more comprehensive information regarding
the effect of a given active agent.
[033] The methods of the invention also find use with pharmacists, who can
prepare patient customized dosages that include an IEM, even if the original
manufacturers of the active agent of interest does not provide dosages that
include an IEM. An IEM is a device that is dimensioned to be ingestible and
includes a conductance control module and a partial power source that is
completed upon contact with conducting fluid. As the IEMs are dimensioned to
be
ingestible, they are sized so that they can be placed in a human mouth and
swallowed. In some instances, IEMs of the invention have a longest dimension
that is 30 mm or less, such as 20 mm or less, including 5 mm or less. As such,
any pharmaceutical composition currently available can be associated with an
IEM using methods and components of the invention.
[034] Following placement of the pharmaceutically active agent composition
(and any optional filler composition as desired) into the internal volume of
the
carrier component, the resultant filled carrier component is then sealed with
a
cap. A cap is a structure configured to mate with the open end of a carrier
component in a sealing relationship, such that when the cap is associated with
the open end of the carrier component, an internal volume of the carrier
8
CA 02750148 2014-12-31
=
component and contents thereof (the pharmaceutically active agent composition)
are sealed from the external environment of the dosage structure defined by
the
carrier and cap, such that gases and liquids may not readily pass between the
external and internal environments of the dosage structure. The cap may be
fabricated from any suitable material, including the materials described above
in
connection with the carrier component. In some instances, the cap is
fabricated
from microcrystalline cellulose, croscarmellose sodium and magnesium stearate.
[035] Caps of the invention include one or more IEM identifiers. The one or
more
IEM may be present at a variety of different locations of the cap, including
internal
locations and external locations. Internal locations include areas defined
inside of
the cap that are configured to receive the IEM. External locations include
outer
and inner surfaces. Outer surfaces of the cap are those surfaces that face the
external environment of the cap when the cap is in a sealing relationship with
the
carrier component. The outer surface may be a side surface of the cap or a top
surface of the cap, as desired. Inner surfaces of the cap are those surfaces
that
face the internal volume defined by the carrier component and cap when the cap
is in a sealing relationship with the carrier component. A given cap may
include a
single IEM or two or more IEMs, such as three or more ingestible event
markers.
[036] The one or more IEMs are stably associated with the cap. As such, the
identifiers are fixed to a location of the cap, such as an outer surface of
the cap,
for example by use of an adhesive. Adhesives of interest include, but are not
limited to: sugar and cellulosic adhesives, protein adhesives such as zein or
casein, silicone adhesives, polymeric adhesives, including acrylic and
methacyrlic
adhesives, shellac, and the like.
[037] IEMs of interest are identifiers that communicate information through
production of a unique current signature that flows through a conducting
environment, such as a conducting fluid, upon contact of the IEM with a target
physiological location (or locations). The IEMs may vary depending on the
particular embodiment and intended application of the composition, as long as
they are activated (turned on) upon contact with a target physiological
location,
such as the stomach fluid or intestinal fluid. As such, an IEM may be an
identifier
that produces a unique current signature encoded with information when
activated at a target site, for example when the IEM contacts a target body
site.
The IEM may be any component or device that is capable of providing a
9
CA 02750148 2014-12-31
detectable signal following activation. IEMs according to various aspects of
the
present invention comprise a control unit for producing a unique current
signature. The IEM may be configured to produce the unique current signature
once the composition comes into contact with a physiological target site.
Depending on the embodiment, the target physiological site or location may
vary,
where representative target physiological sites of interest include, but are
not
limited to: a location in the gastrointestinal tract, such as the mouth,
esophagus,
stomach, small intestine, large intestine, etc. IEMs may be configured to be
activated upon contact with fluid at the target site, e.g., stomach fluid,
regardless
of the particular composition of the target site. Where desired, the
identifier may
be configured to be activated by interrogation, following contact of the
composition with a target physiological site. The IEM may be configured to be
activated after a specific period of time, wherein the target site is reached
after a
specified period of time.
[038] Depending on the needs of a particular application, the information
obtained from the IEM may be generic, such that the information merely
identifies
that the composition has contacted the target site. Alternatively, the
information
may be unique, which in some way uniquely identifies that a particular IEM
from a
group or plurality of different markers in a batch of dosages has contacted a
target physiological site. As such, the IEM may be one that, when employed
with
a batch of dosages, emits a current signature which cannot be distinguished
from
the current signature emitted by the IEM of any other dosage member of the
batch. Alternatively, each IEM of the batch may emit a unique signal, at least
with
respect to all the other IEMs of the batch. In these instances, each IEM of
the
batch produces a current signature that uniquely identifies that particular
IEM with
respect to all other IEMs in the batch. The IEM may emit a unique current
signature that is a universally unique current signature (where such a current
signature may be analogous to a human fingerprint which is distinct from any
other fingerprint of any other individual and therefore uniquely identifies an
individual on a universal level). The current signature may either directly
convey
information about a given event, or provide an identifying code, which may be
used to retrieve information about the event from a database, i.e., a database
linking identifying codes with compositions.
CA 02750148 2014-12-31
[039] The duration of the current generation period of the IEM may vary, in
accordance with the teachings of the present invention, from 0.1 sec to 48
hours
or longer, such as from 0.1 sec to 24 hours or longer, such as from 0.1 sec
to 4
hours or longer, such as from 1 sec to 4 hours, including from 1 minute to 10
minutes. Depending on the given embodiment, the IEM may produce the same
information encoded in the current signature one time; alternatively, the IEM
may
be configured to produce the current signature with the same information
(identical), two or more times, where the collection of discrete identical
current
signatures may be collectively referred to as a redundant signal.
[040] In addition to producing a unique current signature, in accordance with
other aspects of the present invention, the IEM may be configured to generate
a
variety of different types of signals, including but not limited to: RF
signals,
magnetic signals, acoustic signals, etc.
[041] The IEM may vary depending on the particular embodiment and intended
application of the composition so long as they are activated (i.e., turned on)
upon
contact with a target physiological location, such as the stomach. The IEM
includes a partial power source that is completed by a conducting fluid, such
as
stomach acid, and a conductance control unit. Examples of different types of
IEMs of interest include, but are not limited to, those described in PCT
application
serial no. PCT/US2006/016370 published as WO/2006/116718; PCT application
serial no. PCT/US2007/082563 published as WO/2008/052136; PCT application
serial no. PCT/US2007/024225 published as WO/2008/063626; PCT application
serial no. PCT/US2007/022257 published as WO/2008/066617; PCT application
serial no. PCT/US2008/052845 published as WO/2008/095183; PCT application
serial no. PCT/US2008/053999 published as WO/2008/101107; PCT application
serial no. PCT/US2008/056296 published as WO/2008/112577; PCT application
serial no. PCT/US2008/056299 published as WO/2008/112578; PCT application
serial no. PCT/US2008/077753; and U.S. patent application serial no.
12/564,017
filed September 21, 2009.
[042] The cap may have a variety of different configurations so long as it is
configured to seal the open end of the carrier component when it is associated
with the open end of the carrier component. The cap may have a variety of
different configurations which allow it to seal the open end of the carrier
11
CA 02750148 2014-12-31
,
component when associated with the open end of the carrier component. In some
instances, the cap has interlocking elements which operate in conjunction with
mating elements of the open end of the carrier component to seal the open end
of the carrier component. Examples of interlocking elements are screw threads
and snap-fit elements. Alternatively, the cap may have a region or end that is
configured to pressure fit inside of the carrier component and seal the
contents of
the carrier component. An example of such a configuration is where the cap has
an end made up of a rigid material, where the configuration of the end is
slightly
larger than the open end of the carrier component. Where the open end of the
carrier component is made of an elastomeric material, the rigid end of the cap
can be pressure fit into the open end of the carrier by stretching the open
end of
the carrier. When any stretching force is removed from the open end of the
carrier, the open end of the carrier will then comply with the rigid end of
the cap in
a sealing relationship. Alternatively, the cap may include a compressible end
which has a certain amount of compliancy. This compliancy is sufficient to
impart
to the cap the ability to pressure fit the pliable end of the cap inside the
open end
of the carrier component by compressing the compressible end to produce a
compressed end, placing the compressed end of the cap in the open end of the
carrier component and then removing the compressive force. When the
compressed end expands as a result of removal of the compressive force, the
compressed end conforms to the configuration of the open end of the carrier
component in a sealing relationship to seal the contents of the carrier
component
inside of the carrier component.
[043] A cap with a compressible end can be provided in a number of different
ways. One type of compressible end is an end that is fabricated from a
compressible material. Compressible materials of interest are pliable.
Alternatively, the compressible end may include one or more cut-outs that
impart
compressibility to the compressible end.
[044] Where desired, the cap may be secured to the open end of the carrier
component with an adhesive, where examples of suitable adhesives are provided
above. As such, the cap may be glued onto the open end of the carrier
component in order to seal the open end of the carrier component.
[045] In some instances, passageways or analogous structures are provided in
the carrier and/or cap which facilitate liquid penetration of the dosage form,
12
CA 02750148 2014-12-31
dissolution of the carrier components and/or reduce buoyancy of the dosage
form. When present, such holes may range from 10-3 to 5 mm in diameter, such
as 0.1 to 2 mm in diameter.
[046] Referring now to FIGS. 1A and 2A, a pharmaceutical dosage carrier
system 10 includes a cap 20 and housing or housing 50. The housing 50 of the
system 10 defines a cavity and includes an open end 60 and a closed end 70.
The closed end 70 has a partially-planer base with side walls extending from
the
base in an upward direction, finishing with an open mouth at the open end 60
to
define the cavity therein. The closed end 70 may also be a rounded structure,
such as a hemispherical end wall, among other configurations, and have a
conical configuration, etc.
[047] The system 10 includes an engagement area 65 on the inner wall of the
housing 50. The engagement area 65 can be engaged with the cap 20 when the
cap 20 is inserted into the open end 60 of the housing 50 in a manner
sufficient to
produce a seal between the housing 50 and the cap 20. The cap 20 and housing
50 sizes are chosen such that there is contact between the external wall of
the
cap 20 and the internal wall of the engagement area 65 of the housing 50.
[048] As reviewed above, the system 10 may be filled with a pharmaceutically
active agent composition and/or a filler composition. In accordance with one
aspect of the present invention, the system 10 is filled with a
pharmaceutically
active agent composition and two filler compositions that are in the form of
tablets. As such, the housing 50 is filled with a pharmaceutically active
agent
tablet 30 and two filler compositions 35 and 37. Although shown in a specific
order within the cavity defined by the housing 50, the scope of the present
invention is not limited by the relative positions or the order of the tablet
30 and
the filler compositions 35 and 37. For example, the tablet 30 may be
positioned at
the location of filler composition 37 as shown in Fig. 1A. Additionally, the
orientation of the tablet 30 and the filler composition 35 and 37 may be
flipped to
better accommodate assembly of the system 10, as shown in FIGS. 1B and 2B,
and the scope of the present invention is not limited thereby. At least one of
the
filler compositions 35 and 37 are fabricated from a material such that impart
a
density to the overall system 10. In accordance with one aspect of the present
invention, the density may be greater than the density of the environment that
the
system 10 enters or is introduced to, such as stomach fluid. Thus, either one
of
13
CA 02750148 2014-12-31
the filler compositions 35 and 37 can be used to alter the buoyancy of the
system
10; the other filler composition may be used to prevent movement of the tablet
30
and the other filler composition within the cavity defined by the housing 50.
In
accordance with another aspect of the present invention, both of the filler
compositions may be used to alter the buoyancy of the system 10. In accordance
with the teaching of the present invention, either one of filler compositions
may be
replaced by a pharmaceutical agent, such that the system 10 includes two (or
more?) different pharmaceutically active agents that are released into the
surrounding environment at different times or at the same times.
[049] Referring now to FIGS. 1A and 1B, in assembling the system 10, the
pharmaceutically active agent, such as the tablet 30, and the two filler
compositions 35 and 37 are positioned inside of housing 50 as shown. This
positioning step may be accomplished manually or by automatic methods, such
as through the use of an assembly machine, remote robot, or other automated
device. Following placement of the tablet 30 and the filler compositions 35
and 37
into the housing 50, the open end 60 of the housing 50 is sealed with the cap
20
to seal the system 10. Sealing the open end 60 of the housing 50 with the cap
20
may be accomplished manually or by automatic methods, such as through the
use of an assembly machine, remote robot, or other automated device.
[050] As shown in FIGS. 1A and 2A, the cavity defined by the housing 50 that
contains the tablet 30 as well as the filler compositions 35 and 37 is sealed
with
the cap 20. The cap 20 may be pressure-fit inside of the open end 60 of the
housing 50. In accordance with another aspect of the present invention, the
cap
20 may be glued to the engagement area 65.
[051] Referring now to FIGS. IA and 2A, the cap 20 includes a device 40, such
as an IEM, on a top-outer surface thereof. The device 40 is secured to the
upper
surface of the cap 20 through the use of a suitable securing method. For
example, in accordance with one aspect of the present invention the device 40
is
glued to the cap 20 using a suitable adhesive. Alternatively, as shown in FIGS
1B
and 2B, the device 40 maybe secured to a bottom-inner surface of the cap 20
such that when the cap 20 is positioned within the cavity of the housing 50,
the
device 40 is sealed therein and protected from contact with the surrounding
environment that the system 10 is introduced to until the cap 20 is released
from
the housing 50.
14
CA 02750148 2014-12-31
[052] In accordance with another aspect of the present invention, the device
40
includes a virtual dipole element as described in PCT application serial no.
PCT/US2008/077753. In accordance with other aspect of the present invention,
the device 40 may not be visible.
[053] Referring now to FIGS. 1A and 2A, the cap 20 includes an insertion
portion 80 that is fitted into the open end 60 of the housing 50, as described
above. The insertion portion 80 is opposite the surface on which the device 40
is
positioned. As shown, the insertion portion 80 defines at least one cut-out
portion
90 that allows the insertion portion 80 to be fitted inside of the open end
60. The
open end 60 may be malleable to stretch over and pressure fit onto the
insertion
portion 80 and provide for a secure fit. As such, the cap 20 may be pinched to
fit
into the open end 60 of the housing 50 when used to seal the insertion portion
80
into the open end 60.
[054] Referring now to FIGS. 1B and 2B, the cap 20 includes an insertion
portion 80 that is fitted into the open end 60 of the housing 50, as described
above. The insertion portion 80 is located proximal to the bottom surface of
the
cap 20. The bottom surface of the cap 20 is shaped to receive the device 40
that
is positioned on and secured to the bottom surface. As shown, the insertion
portion 80 defines a plurality of cut-out portions 90 that allows the
insertion
portion 80 to be fitted inside of the open end 60. However, the scope of the
present invention is not limited by the shape or the number of cut-out
portions on
the bottom surface of the cap 20. The open end 60 may be malleable to stretch
over and pressure fit onto the insertion portion 80 and provide for a secure
fit.
Alternatively and in accordance with another aspect of the present invention,
the
open end 60 may be rigid and tapered (not shown) to matingly receive a tapered
insertion portion (not shown) of the cap 20, wherein the tapered portion or
the
open end 60 and the tapered insertion portion of the cap 20 are glued
together.
As such, the cap 20 may be pressed and glued into the open end 60 of the
housing 50 to secure the cap 20 to housing 50.
[055] Referring now FIGS. 3A, 3B, and 3C, the cap 20 includes the insertion
portion 80. In accordance with one aspect of the present invention, the
insertion
portion 80 defines four channels or cut-outs 92, 94, 96 and 98. Each cut-out
has
a near-crescent shape, as shown. However, the cut-outs 92, 94, 96, and 98 may
have any suitable shape that facilitates fitting of the cap 20 into the open
end 60,
CA 02750148 2014-12-31
such as a polygonal shape. As shown, the insertion portion 80 of the cap 20
includes a circumferential annular beveled ridge.
[056] In some instances, the cap 20 that is secured to the end of the housing
50
may be covered by an over-cap component. The over-cap component may be
fabricated from a variety of materials, such as any of the materials employed
for
the carrier component. The over-cap may be fabricated from an opaque material
so as to hide the presence of a device 40 as well as prevent contact with the
surrounding during packaging and handling. The over-cap component may be
elastomeric, for example to provide for a secure fit over the cap that is in
sealing
relation with the carrier component.
[057] Referring now to FIG. 4, in accordance with another aspect of the
present
invention a pharmaceutical dosage system 130 includes an over-cap 132. The
pharmaceutical dosage system 130 includes a carrier component 140 sealed with
a cap 134. The cap 134 includes a device 136, such as a current signature
production device or IEM, on an outer surface thereof. Positioned over cap 134
is
the over-cap 132. The over-cap 132 is secured to the carrier component 140 as
shown; this prevents contact between the device 136 and conducting fluid once
the pharmaceutical dosage system 130 is ingested. Once the over-cap 132 is
released from the carrier component 140, the device 136 comes into contact
with
the surrounding environment and if that environment includes a conducting
fluid,
such as stomach fluid, then the device 136 is activated and produces a current
signature that can be detected and decoded to retrieve information.
[058] Where desired, the methods of preparing the dosage delivery system may
further include preparing placebo pharmaceutical dosages. Placebo
pharmaceutical dosages may be prepared in a manner analogous to the
preparation of dosages that include a pharmaceutically active agent, with the
exception that a pharmaceutically active agent is not placed inside of a
carrier
component. Instead, a vehicle composition that lacks an active agent, for
example as described above, is placed inside of the carrier component and then
sealed with the cap. Methods where placebo dosages are prepared include
methods in which the pharmaceutical dosages are to be employed in clinical
trials.
[059] In accordance with yet another aspect of the present invention, the
methods of preparing a dosage delivery system may further include preparing
16
CA 02750148 2014-12-31
dosages having a device within the carrier, e.g., either alone or in
combination
with a filler. Such aspects may facilitate, among other applications, marking
of
an ingestion event of the dosage delivery system via production of a unique
current signature.
[060] In accordance with another aspect of the present invention, two
different
pharmaceutical agents may be placed within the housing 50 and separated by a
filler composition. This physical separation is beneficial in instances where
to
different pharmaceutical agents must be mixed in solution to become active.
Thus, as the housing 50 is dissolved, the two separate pharmaceutical agents
are released into the surrounding fluid, such as the stomach fluid. This
causes
the two previously separated pharmaceutical agents to come into contact and
combine, thereby allowing accurate delivery and combination of two different
pharmaceutical agents at a target site.
[061] Aspects of the invention further include methods of using the
pharmaceutical dosages that are produced according to methods as described
above. Generally, methods of the invention will include administering one or
more
pharmaceutical dosages to a subject, for example by having a subject ingest a
pharmaceutical dosage of the invention. The dosages may be administered to a
variety of different types of subjects. Generally such subjects are "mammals"
or
"mammalian," where these terms are used broadly to describe organisms which
are within the class mammalia, including the orders carnivore (for example
dogs
and cats), rodentia (for example mice, guinea pigs, and rats), and primates
(for
example humans, chimpanzees, and monkeys). Following ingestion, a unique
current signature is produced by an IEM and detected, for example with a
receiver, such as described in PCT application serial no. PCT/US2006/016370
published as WO/2006/116718; PCT application serial no. PCT/US2007/082563
published as WO/2008/052136; PCT application serial no. PCT/US2007/024225
published as WO/2008/063626; PCT application serial no. PCT/U52007/022257
published as WO/2008/066617; PCT application serial no. PCT/US2008/052845
published as WO/2008/095183; PCT application serial no. PCT/US2008/053999
published as WO/2008/101107; PCT application serial no. PCT/US2008/056296
published as WO/2008/112577; PCT application serial no. PCT/US2008/056299
published as WO/2008/112578; PCT application serial no. PCT/US2008/077753;
17
CA 02750148 2014-12-31
U.S. patent application serial no. 61/251,088 filed October 13, 2009; and PCT
patent application serial no. PCT/US2009/068128 filed December 15, 2009.
[062] Methods of preparing pharmaceutical dosages and administering the
same to subjects, for example as described above, find use in a variety of
different applications. One application of interest is the use of the
identifiers of the
dosages as IEMs. Pharmaceutical dosages of the invention can be used in both
therapeutic and non-therapeutic applications, such as reviewed in PCT
application serial no. PCT/US2006/016370 published as WO/2006/116718; PCT
application serial no. PCT/US2007/082563 published as WO/2008/052136; PCT
application serial no. PCT/US2007/024225 published as WO/2008/063626; PCT
application serial no. PCT/US2007/022257 published as WO/2008/066617; PCT
application serial no. PCT/US2008/052845 published as WO/2008/095183; PCT
application serial no. PCT/US2008/053999 published as WO/2008/101107; PCT
application serial no. PCT/US2008/056296 published as WO/2008/112577; PCT
application serial no. PCT/US2008/056299 published as WO/2008/112578; and
PCT application serial no. PCT/US2008/077753.
[063] Applications of interest include automatic detection and identification
of
pharmaceutical agents actually delivered into the body, as may be done in: (1)
monitoring patient adherence with prescribed therapeutic regimens; (2)
tailoring
therapeutic regimens based on patient adherence; (3) monitoring patient
adherence in clinical trials; (4) monitoring usage of controlled substances;
and
the like. Each of these different illustrative applications is reviewed in
greater
detail in PCT application serial no. PCT/US2006/016370 published as
WO/2006/116718; PCT application serial no. PCT/US2007/082563 published as
WO/2008/052136; PCT application serial no. PCT/US2007/024225 published as
WO/2008/063626; PCT application serial no. PCT/US2007/022257 published as
WO/2008/066617; PCT application serial no. PCT/US2008/052845 published as
WO/2008/095183; PCT application serial no. PCT/US2008/053999 published as
WO/2008/101107; PCT application serial no. PCT/US2008/056296 published as
WO/2008/112577; PCT application serial no. PCT/US2008/056299 published as
WO/2008/112578; and PCT application serial no. PCT/US2008/077753.
[064] In certain embodiments, the methods of making pharmaceutical dosages
of the invention are employed in clinical trials. Clinical trials in which the
methods
and compositions of the invention include multi-patient studies that are
conducted
18
CA 02750148 2014-12-31
to allow safety and efficacy data to be collected for a new pharmaceutically
active
agent. Examples of clinical trials include studies where investigators enroll
healthy volunteers and/or patients into small pilot studies initially,
followed by
larger scale studies in patients that often compare the new product with a
currently prescribed treatment. Furthermore, clinical trials may also compare
the
active agent of interest with a placebo composition. In these instances,
placebos
may be produced in a manner analogous to the methods of producing
pharmaceutical dosages of the invention, with the only difference being that a
pharmaceutically active agent composition is not sealed the carrier component.
As positive safety and efficacy data are gathered in a given clinical trial,
the
number of patients may be increased. Clinical trials can vary in size from a
single
center in one country to multi-center trials in multiple countries.
[065] Performing clinical trials with pharmaceutical dosages prepared
according
to the invention provides a number of advantages. One advantage is that the
clinical trial manager (the entity who is running the clinical trial) can use
standard
carrier components and caps and customize these as needed with a given
pharmaceutically active agent composition.
[066] Also provided are systems that include one more pharmaceutical dosages
of the invention, as described above. In addition to the pharmaceutical
dosages
of the invention, the systems may include body-associated signal receivers for
detecting changes in voltage potential that represent receiving encoded
information from a pharmaceutical dosage carrier in accordance with the
teaching
of the present invention. Body-associated receivers of interest include those
described in PCT/US2008/052845 published as WO/2008/095183 and
PCT/US2006/016370 published as WO/2006/116718. As described in these
incorporated applications, the receivers may be implanted or on a body surface
of
a patient. The systems may further include additional data relay and/or
processing components, such as wireless communication devices (such as cell
phones); data processors as may be found in computers and information
systems, etc.
[067] Also provided are kits for practicing the subject methods. Kits may
include
one or more carrier components and associated caps of the invention, as
described above. The carrier components and associated caps of the kits will
be
equipped to receive a dosage amount of one or more pharmaceutically active
19
CA 02750148 2014-12-31
agent compositions to be sealed therein; such as pharmaceutically active agent
compositions being provided separately from the instant kits. Where desired,
the
kits may also include one or more filler compositions. A given kit may include
sufficient carrier components and caps to make 1 or more, including 5 or more,
such as 50 or more, 100 or more, 1000 or more, 5000 or more, or 10000 or more
pharmaceutical dosages.
[068] The subject kits may also include instructions for how to practice the
subject methods using the components of the kit. The instructions may be
recorded on a suitable recording medium or substrate. For example, the
instructions may be printed on a substrate, such as paper or plastic, etc. As
such,
the instructions may be present in the kits as a package insert, in the
labeling of
the container of the kit or components thereof (i.e., associated with the
packaging
or sub-packaging) etc. In other embodiments, the instructions are present as
an
electronic storage data file present on a suitable computer readable storage
medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual
instructions are not present in the kit, but means for obtaining the
instructions
from a remote source, e.g. via the internet, are provided. An example of this
embodiment is a kit that includes a web address where the instructions can be
viewed and/or from which the instructions can be downloaded. As with the
instructions, this means for obtaining the instructions is recorded on a
suitable
substrate.
[069] Some or all components of the subject kits may be packaged in suitable
packaging to maintain sterility. Where desired, the components of the kit are
packaged in a kit containment element to make a single, easily handled unit,
where the kit containment element may be a box or analogous structure and may
or may not be an airtight container.
[070] It is to be understood that this invention is not limited to particular
embodiments described, as such may vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
embodiments
only, and is not intended to be limiting, since the scope of the present
invention
will be limited only by the appended claims.
[071] Where a range of values is provided, it is understood that each
intervening
value, to the tenth of the unit of the lower limit unless the context clearly
dictates
otherwise, between the upper and lower limit of that range and any other
stated
CA 02750148 2016-05-05
or intervening value in that stated range, is encompassed within the
invention.
The upper and lower limits of these smaller ranges may independently be
included in the smaller ranges and are also encompassed within the invention,
subject to any specifically excluded limit in the stated range. Where the
stated
range includes one or both of the limits, ranges excluding either or both of
those
included limits are also included in the invention.
[072] Unless defined otherwise, all technical and scientific terms used herein
have the same meaning as commonly understood by one of ordinary skill in the
art to which this invention belongs. Although any methods and materials
similar
or equivalent to those described herein can also be used in the practice or
testing
of the present invention, representative illustrative methods and materials
are
now described.
[073] The dates of publication provided may be different from the actual
publication dates which may need to be independently confirmed.
[074] It is noted that, as used herein, the singular forms "a", "an", and
"the"
include plural referents unless the context clearly dictates otherwise.
[075] Certain ranges have been presented herein with numerical values being
preceded by the term "about." The term "about" is used herein to provide
literal
support for the exact number that it precedes, as well as a number that is
near to
or approximately the number that the term precedes. In determining whether a
number is near to or approximately a specifically recited number, the near or
approximating unrecited number may be a number which, in the context in which
it is presented, provides the substantial equivalent of the specifically
recited
number.
[076] As will be apparent to those of skill in the art upon reading this
disclosure,
each of the individual embodiments described and illustrated herein has
discrete
components and features which may be readily separated from or combined with
the features of any of the other several embodiments. Any recited method can
be
carried out in the order of events recited or in any other order which is
logically
possible.
21
CA 02750148 2014-12-31
..
[077] Although the foregoing invention has been described in some detail by
way of illustration and example for purposes of clarity of understanding, it
is
readily apparent to those of ordinary skill in the art in light of the
teachings of this
invention that certain changes and modifications may be made thereto.
22
